Metabasis Therapeutics, Inc.

Ferring B.v.

Edward Earl Cable

Mark D Erion

Jacek Stalewski

The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

Thyromimetics for the treatment of fatty liver diseases

Compounds of formula (I) and pharmaceutically acceptable salts thereof are described:AA1-Arg-Val-AA4-AA5-His-Pro-AA8-OH&#x2003;&#x2003;(I),in which AA1, AA4, AA5, and AA8 are defined in the specification. The compounds of formula (I) can be used to treat hypertension (e.g., hypertension induced by pregnancy), preeclampsia, or a renal disease induced by pregnancy.

Growing community of inventors

San Diego, CA, United States of America

Edward Earl Cable